Yes, the intention is to take Yervoy+Cavatak to phase 3, almost certainly for pd-1/pd-l1 inhibitor failed (refractory) patients, i.e those who have failed to respond to keytruda, opdivo (or Lepu's similar products).
VLA Price at posting:
77.0¢ Sentiment: Hold Disclosure: Held
